Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Mona Lisa Alattar, MD, Jorge E. Cortes, Susan O'Brien, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Farhad Ravandi, MD, Elias Jabbour, Jianqin Shan, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2749.

https://doi.org/10.1182/blood.V118.21.2749.2749

Published: 2011

Journal Articles

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Alfonso QuintÀs-Cardama, MD, Hawk Kim, MD, Jianqin Shan, PhD, Elias Jabbour, Stefan Faderl, MD, William G. Wierda, MD, PhD, Farhad Ravandi, MD, Tapan Kadia, Sa A. Wang, MD, Sherry Pierce, RN, BS, Hagop M Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (21): 967.

https://doi.org/10.1182/blood.V118.21.967.967

Published: 2011

Journal Articles

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

Farhad Ravandi, MD, Stefan Faderl, MD, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Mark Brandt, BS, Jianqin Shan, PhD, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Susan o'Brien, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 3569.

https://doi.org/10.1182/blood.V118.21.3569.3569

Published: 2011

Journal Articles

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Farhad Ravandi, MD, Deborah A. Thomas, MD, Susan O'Brien, MD, Rebecca Garris, BSc, Stefan Faderl, MD, Jianqin Shan, PhD, Gautam Borthakur, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Partow Kebriaei, MD, Richard Champlin, MD, Zeev Estrov, Sa A. Wang, MD, Jeffrey L. Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 1453.

https://doi.org/10.1182/blood.V118.21.1453.1453

Published: 2011

Journal Articles

Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).

Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Susan O'Brien, Srdan Verstovsek, MD, PhD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jianqin Shan, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 3438.

https://doi.org/10.1182/blood.V116.21.3438.3438

Published: 2010

Journal Articles

Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index

Kiran Naqvi, MD, Maria E Suarez-Almazor, MD, PhD, Sagar Sardesai, MD, Jeong Oh, MD, MPH, Carlos Vigil, MD, Sherry Pierce, RN, BS, Xiudong Lei, PhD, Jianqin Shan, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 605.

https://doi.org/10.1182/blood.V116.21.605.605

Published: 2010

Journal Articles

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

Hagop Kantarjian, MD, Susan O'Brien, MD, Elias Jabbour, MD, Jianqin Shan, PhD, Farhad Ravandi, MD, Tapan Kadia, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD

Blood (2010) 116 (21): 672.

https://doi.org/10.1182/blood.V116.21.672.672

Published: 2010

Journal Articles

Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Jianqin Shan, PhD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Susan O'Brien, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1234.

https://doi.org/10.1182/blood.V116.21.1234.1234

Published: 2010

Journal Articles

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Pamela S. Becker, MD, PhD, Hagop Kantarjian, MD, Frederick R. Appelbaum, MD, Stephen H. Petersdorf, MD, Barry Storer, PhD, Sherry A. Pierce, RN, BS, Jianqin Shan, PhD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Andrei Shustov, MD, Derek L. Stirewalt, MD, Stefan Faderl, MD, Elizabeth Harrington, RN, Elihu H. Estey, MD

Blood (2010) 116 (21): 1065.

https://doi.org/10.1182/blood.V116.21.1065.1065

Published: 2010

Journal Articles

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Wei-gang Tong, MD, PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD, William Wierda, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3819.

https://doi.org/10.1182/blood.V114.22.3819.3819

Published: 2009

Journal Articles

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Hawk Kim, MD, Elias Jabbour, MD, Tapan Kadia, MD, Gautam Borthakur, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes, MD, Farhad Ravandi, MD, William G Wierda, Zeev Estrov, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3796.

https://doi.org/10.1182/blood.V114.22.3796.3796

Published: 2009

Journal Articles

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Jianqin Shan, PhD, Jan Davisson, RN, Jean-Pierre Issa, MD

Blood (2007) 110 (11): 115.

https://doi.org/10.1182/blood.V110.11.115.115

Published: 2007

Journal Articles

High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.

tsuko Aoki, MD, Hagop Kantarjian, MD, Susan O’Brien, MD, Moshe Talpaz, MD, Francis Giles, MD, Srdan Verstovsek, MD, William Wierda, MD, August Salavado, MD, Lauri Letvak, MD, Guillermo Garcia-Manero, MD, Dan Jones, MD, Rajyalakshmi Luthra, PhD, Jianqin Shan, PhD, Jorge Cortes, MD

Blood (2006) 108 (11): 2143.

https://doi.org/10.1182/blood.V108.11.2143.2143

Published: 2006

Journal Articles

Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.

Elias Jabbour, MD, Hagop Kantarjian, MD, Miloslav Beran, MD, PhD, DVM, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Sherry Pierce, RN, BSN, BA, Jianqin Shan, PhD, William Plunkett, MD, PhD, Michael Keating, MD, Elihu Estey, MD

Blood (2005) 106 (11): 2529.

https://doi.org/10.1182/blood.V106.11.2529.2529

Published: 2005

Journal Articles

Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).

Etsuko Aoki, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Mary Beth Rios, R.N., Farhad Ravandi, MD, Srdan Verstovsek, MD, Guillermo Garcia-Manero, MD, Jianqin Shan, PhD, Jorge Cortes, MD

Blood (2005) 106 (11): 1103.

https://doi.org/10.1182/blood.V106.11.1103.1103

Published: 2005

Journal Articles

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O’Brien, MD, Jorge Cortes, MD, Francis Giles, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Sherry Pierce, RN, BSN, BA, Jianqin Shan, PhD, Elihu Estey, MD

Blood (2005) 106 (11): 1846.

https://doi.org/10.1182/blood.V106.11.1846.1846

Published: 2005

Journal Articles

Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.

Ricardo H. Alvarez, M.D., Hagop M. Kantarjian, M.D., Carlos Bueso-Ramos, M.D., PhD, Moshe Talpaz, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Mary Beth Rios, Jianqin Shan, PhD, Jorge Cortes, M.D.

Blood (2004) 104 (11): 2939.

https://doi.org/10.1182/blood.V104.11.2939.2939

Published: 2004

NARROW

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).

Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.

Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.

Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only